Clinical trials: Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)
This study will be conducted to evaluate the safety, efficacy and pharmacokinetics of belimumab administered in combination with background standard therapy in pediatric participants with active SLE.
- Trial name
- NCT04908865
- Testing
- Belimumab, Standard therapy
- Where
- 9 sites in China
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and…
- Trial name
- NCT06576271
- Testing
- GSK4527363, Belimumab
- Where
- 28 sites in United States, Argentina and 4 more
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
The purpose of this study is to obtain skin, blood, and urine samples from patients with active cutaneous lupus lesions and from healthy participants.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy
- Trial name
- NCT02034344
- Testing
- Skin biopsy, Blood collection, Urine collection
- Where
- 21 sites in United States, Germany and 4 more
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Systemic Lupus Erythematosus
Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the safety and efficacy of Epratuzumab with standard treatments for patients with SLE.
- Trial name
- NCT00383214
- Testing
- Epratuzumab
- Where
- 60 sites in United States, Belgium and 9 more
- Volunteers
- 54 people
- Sponsor
- UCB Pharma
Lupus Erythematosus, Systemic
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus (SLE - chronic disorder of connective tissue in…
- Trial name
- NCT02349061
- Testing
- Ustekinumab IV, Ustekinumab SC, Concomitant Medication
- Where
- 43 sites in United States, Argentina and 7 more
- Volunteers
- 102 people
- Sponsor
- Janssen Research & Development, LLC
Systemic Lupus Erythematosus
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
- Trial name
- POETYK SLE-1 (NCT05617677)
- Testing
- Deucravacitinib
- Where
- 197 sites in United States, Argentina and 20 more
- Volunteers
- 516 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
- Trial name
- NCT06456567
- Testing
- Telitacicept
- Where
- 4 sites in United States
- Sponsor
- Vor Biopharma
Systemic Lupus Erythematosus
A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
This is a study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).
- Trial name
- NCT02908100
- Testing
- GDC-0853
- Where
- 70 sites in United States, Argentina and 10 more
- Volunteers
- 260 people
- Sponsor
- Genentech, Inc.
Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and…
- Trial name
- NCT06570798
- Testing
- Inebilizumab, Blinatumomab
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 220 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
- Trial name
- POETYK SLE-2 (NCT05620407)
- Testing
- Deucravacitinib
- Where
- 180 sites in United States, Argentina and 20 more
- Volunteers
- 513 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus (SLE)
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care…
- Trial name
- NCT04058028
- Testing
- Rozibafusp Alfa
- Where
- 147 sites in United States, Argentina and 17 more
- Volunteers
- 244 people
- Sponsor
- Amgen
Active Systemic Lupus Erythematosus
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic…
- Trial name
- NCT02446912
- Testing
- Anifrolumab
- Where
- 145 sites in United States, Argentina and 16 more
- Volunteers
- 460 people
- Sponsor
- AstraZeneca
Lupus Erythematosus, Systemic, Lupus Erythematosus
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
To compare the effect of RAYOS® versus immediate-release (IR) prednisone on fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).
- Conditions
- Lupus Erythematosus, Systemic, Lupus Erythematosus, Fatigue
- Trial name
- RIFLE (NCT03098823)
- Testing
- RAYOS, Prednisone
- Where
- 21 sites in United States
- Volunteers
- 62 people
- Sponsor
- Ampel BioSolutions, LLC
Systemic Lupus Erythematosus (SLE)
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE).
- Trial name
- EMERALD (NCT05352919)
- Testing
- Litifilimab
- Where
- 214 sites in United States, Argentina and 26 more
- Volunteers
- 864 people
- Sponsor
- Biogen
Systemic Lupus Erythematosus (SLE)
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
- Trial name
- NCT02804763
- Testing
- Dapirolizumab pegol (DZP)
- Where
- 71 sites in United States, Bulgaria and 11 more
- Volunteers
- 182 people
- Sponsor
- UCB Biopharma S.P.R.L.
Systemic Lupus Erythematosus
Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus
To assess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.
- Trial name
- NCT06297408
- Testing
- Relma-cel
- Volunteers
- 24 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Phase Ib Study of SC Milatuzumab in SLE
Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System
- Trial name
- NCT01845740
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Gilead Sciences
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
The purpose of this study is to evaluate the long-term safety and efficacy of orally administered enpatoran in participants with cutaneous manifestations of lupus erythematosus who have completed the Elowen-1 (MS504908_0001)…
- Trial name
- NCT07840287
- Testing
- Enpatoran
- Where
- 2 sites in United States, Germany
- Volunteers
- 404 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Systemic Lupus Erythematosus
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.
- Trial name
- NCT00624351
- Testing
- Epratuzumab
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 227 people
- Sponsor
- UCB Pharma
Lupus Nephritis
Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)
Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).
- Trial name
- NCT05540665
- Testing
- Daxdilimab
- Where
- 52 sites in United States, Argentina and 10 more
- Volunteers
- 19 people
- Sponsor
- Amgen